-
Featured
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from Massachusetts General Hospital seeks to find the answer.
-
Featured
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
-
Featured
Using Immunotherapy to Treat Brain Tumors
In this video, William Curry, MD, discusses advancements in immunotherapy to target brain tumors. In clinical trials, he has seen the safety and strong immune activity of vaccinating patients with their own tumor cells, which has made him optimistic about the future of treatment for patients with brain tumors.
Immuno-Oncology Contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
Co-transplantation of Regulatory T Cells Improves Cell Replacement Therapy for Parkinson's Disease
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Brigham Cancer Institute, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Kerry L. Reynolds, MD
Clinical Director, Inpatient Oncology Units, Director, Severe Immunotherapy Complications Program
Recent Article
Researchers Chart the Course of Severe Checkpoint Inhibitor-related Colitis -
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Preclinical Education Group Leader, Associate Professor of Medicine, Harvard Medical School
Recent Article
Case Series: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
-
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Considering Both Tumor and Immune Features May Improve Prediction of Melanoma Outcomes After Checkpoint Inhibition
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.